<DOC>
	<DOCNO>NCT00964249</DOCNO>
	<brief_summary>This randomize , double blind , placebo control , parallel-group , 7 day repeat dose study investigate safety , tolerability , pharmacokinetics pharmacodynamics inhale dose GW642444M novel dry powder device healthy Japanese male subject .</brief_summary>
	<brief_title>Phase I Study GW642444M Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Japanese healthy male subject age 20 64 year age inclusive . Healthy subject define individual free clinically significant illness disease determine medical history , physical examination , laboratory study , test . 2 . Body weight ≥ 50kg BMI within range 18.525.0kg/m2 inclusive . 3 . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history ( Pack year = ( cigarette per day smoked/20 ) x number year smoke ) ) 4 . Normal spirometry ( FEV1 ≥ 80 % predict , FEV1/FVC ≥ 70 % ) . 5 . Clinical laboratory test data obtain screen meet following : AST ( GOT ) , ALT ( GPT ) , totalbilirubin : upper limit normal range 6 . Serum potassium glucose within normal range screen 7 . Normal 12lead EGC find screening ; QTc interval &lt; 450msec 8 . A mean heart rate within range 4090 beat per minute ( bpm ) inclusive screening . 9 . A mean blood pressure low 140/90mmHg screening . 10 . Capable give write informed consent , include compliance requirement restriction list consent form . 11 . Capable use novel dry powder inhaler . 1 . The subject clinically relevant abnormality medical examination , vital sign , clinical laboratory test medical history screen medical opinion investigator subject medical history consider eligible inclusion study investigator . 2 . The subject currently participate another clinical study postmarketing study subject expose investigational noninvestigational drug device . 3 . The subject participate clinical study investigational noninvestigational drug device previous 4 month . 4 . A history breathing problem ( i.e . history asthmatic symptomatology , asthma childhood ) . 5 . The subject allergy drug idiosyncrasy 6 . The subject know allergy hypersensitivity milk protein excipients lactose monohydrate magnesium stearate . 7 . The subject history current condition drug abuse alcoholism . 8 . History regular alcohol consumption exceed average , 14 drinks/week ( 1 drink=5 ounce ( 150mL ) wine 350mL beer 1.5 ounce ( 45mL ) 80 proof distil spirit ) within 6 month screening . 9 . The subject positive urine drug screening . 10 . Use prescription nonprescription drug , include CYP3A/PGP inhibitor , vitamin , herbal dietary supplement ( include St John'sWort ) within 14 day prior first dose study medication . 11 . The subject positive syphilis , HBs antigen , HCV antibody , HIV antibody , HTLV1 antibody . 12 . The subject donate unit blood `` &gt; 400mL '' within previous 4 month `` &gt; 200mL '' within previous 1 month .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>